Director, Global Hematology, Nephrology & Transplant Finance Business Partner

At Alexion, AstraZeneca Rare Disease, we put patients first and strive to meet their unmet needs worldwide. Working here means being entrepreneurial, thinking big and working together to make the impossible a reality. If you are swift to action, confident to lead, willing to collaborate, and curious about what science can do, then you are our kind of person.

The Rare Disease Business Unit is a dynamic, cross-functional, and cross-market organization that champions our commitment to playing to win. By harnessing the power of our unprecedented pipeline of new molecules and indications, we are driving transformative launches across multiple markets. As we continue to expand our geographical presence globally, we are dedicated to delivering meaningful impact for patients and setting new standards for innovation in rare disease treatment.

As the Director Global TA Finance Business Partner, you will be a key leader within the finance team and play a pivotal role in every aspect of the business and channel our commercial and financial capabilities to make a positive impact on changing patients' lives.

Reporting to the VP, Global Head of Finance Commercial, this opportunity will provide high quality and impactful financial leadership to the Hematology, Nephrology and Transplant Global Leadership Team.

Focusing on the Hematology, Nephrology and Transplant Global Strategy, you will partner closely with the Global Disease Area Head and the LT team to deliver a coherent strategy to the Senior Executive Team. The Finance Director will also be tasked with providing a clear view of priorities and resource allocation to maximize the franchise business. Furthermore, this role will be pivotal in ensuring that financial performance, discipline and budget control is achieved.

• Business Partnering with the Global Disease Area Head (Hematology, Nephrology and Transplant) and members of the Global Marketing and Market Access (GMMA) Leadership Team.
• Collaborate with senior global stakeholders to deliver a coherent strategy to the Senior Executive Team and provide a clear view of priorities and resource allocation to drive revenue growth and maximize profitability at the Disease Area (DA) businesses level.
• Lead franchise level global performance tracking, insights and analytics monthly in collaboration with global and regional partners through the MBR (Management Business Review) meetings that are organized monthly.
• Engage with R&D Finance ahead of investment decisions and TA strategy to better understand the assumptions and value of Ph3 investment decisions and propose new opportunities, highlighting any TA value implications.
• Provide finance leadership to the (Hematology, Nephrology and Transplant) TA Team in delivering a coherent TA strategy to SET, ensuring a clear view of prioritization, resource allocation, and overall ambition of the TA.
• Lead the (Hematology, Nephrology and Transplant) DA Team in developing both the Long-Term Plan (LTP) and Middle Term Plan (MTP) strategic forecasts, ensuring a strong focus on driving revenue growth and optimizing resource allocation at the brand/indication and regional/market levels to maximize impact and deliver measurable results.
• Lead the Quarterly Business Review (QBR) process for the TA.
• Working cross-functionally and ensuring key Investor Relations questions and discussion points are anticipated and answered.
• Understanding, managing, and influencing the TA/brand P&L and performance against budget and support with optimal resource allocation across products/indications and markets.

Location: Barcelona - Spain (3 days working from the office and 2 days working from home)